Sanofi Launches AccelRare AI Diagnostic Tool in India Following Class A Medical Device Classification

Sanofi's entry of AccelRare into the Indian market signals a regulatory pathway that pharma companies with digital health ambitions in emerging markets will want to map carefully. The web-based pre-diagnostic tool, designed to support identification of suspected rare diseases, has been classified by Indian regulators as a Class A (non-sterile and non-measuring) medical device, the lowest-risk tier under India's Medical Devices Rules, 2017, establishing a precedent for how AI-assisted clinical decision-support software is categorised domestically.

The Class A designation carries comparatively lighter pre-market requirements than Class B, C, or D devices, but it does not exempt manufacturers from post-market surveillance obligations or quality management expectations aligned with ISO 13485. For regulatory affairs leads at companies evaluating similar AI-driven tools, the classification outcome clarifies that software functioning as a pre-diagnostic aid, rather than a diagnostic conclusion engine, can navigate India's device framework without the burden of clinical performance data submissions required at higher risk tiers.

AccelRare operates as a web-based platform, positioning it outside the sterile manufacturing and process validation considerations that dominate traditional pharma operations. That said, pharma companies expanding into digital health portfolios will need to account for software lifecycle management requirements, including change control protocols and validation documentation that parallel, in structure if not in regulation, the 21 CFR Part 11 and ICH Q10 frameworks familiar to GMP-regulated sites.

Rare disease diagnostics carry a distinct operational weight in India, where the average time to diagnosis for rare conditions can extend years beyond presentation. AccelRare's pre-diagnostic function is intended to reduce that interval by flagging symptom patterns consistent with rare disease profiles, supporting earlier referral to specialist care. Sanofi has an established rare disease portfolio globally, and the India deployment aligns with broader industry movement toward integrating digital tools into patient identification pathways ahead of treatment initiation.

For pharma companies watching this space, the more consequential question is whether India's regulators will maintain the Class A classification standard as AI diagnostic tools grow in clinical specificity, or whether future guidance will introduce a reclassification mechanism tied to algorithm performance thresholds.

Source: Media4Growth via Indian Pharma Post, 31 May 2026.